**Indications:**
Azathioprine and mercaptopurine have immunosuppressive and steroid-sparing properties. It is used locally for resistant or frequently relapsing Crohn’s disease and Ulcerative Colitis, and also for dermatological / rheumatological conditions. Treatment for patients with Crohn’s disease (unlicensed indication) must be initiated on Consultant Gastroenterologist advice only.

*Mercaptopurine may be used in IBD when patients are unable to tolerate azathioprine.*

**Dosage and administration:**

**Azathioprine**
The usual starting dose is 50mg daily for 4 weeks. If thiopurine S-methyltransferase (TPMT) is low, patients should be started on 25mg. This should be increased to 100mg daily and, depending on response and haematological tolerance, to a typical maintenance dose of 2-2.5mg/kg/day. When the therapeutic response is evident, this dose can be maintained, although consideration can be given to reducing the maintenance dose to the lowest level that maintains the response. Patients with renal or hepatic insufficiency should be given the lowest effective dose. Azathioprine is taken as a single dose after food.

**Mercaptopurine**
The usual starting dose is 50mg daily for 4 weeks. If TPMT is low, patients should be started on 25mg. This should be increased to 75mg daily and, depending on response and haematological tolerance, to a typical maintenance dose of 1-1.5mg/kg/day.

**Additional Information**
- Mercaptopurine is the active metabolite of azathioprine.
- Pneumovax® II and annual influenza vaccine is recommended.
- Vaccination for varicella zoster prior to treatment with a 3 week window before commencing treatment in those with negative varicella zoster serology is advised if no contraindication.
- Passive immunisation should be carried out in non-immune patients exposed to chickenpox or shingles, using Varicella Zoster Immunoglobulin.

**Monitoring requirements:**

**Before treatment:**
- Full blood count (FBC) including platelets, urea and electrolytes (U&Es), creatinine and liver function tests (LFTs) (hospital)
- Test for thiopurine methyl transferase (TPMT), as a deficiency increases the risk of myelosuppression.

**During treatment:**
- FBC weekly for the first four weeks, then monthly for 3 months thereafter if stable. Once fully stabilised, monitoring can be every 3 months.
- LFTs and U&Es weekly for the first four weeks, then monthly thereafter if stable.
- If dose is increased, repeat FBC and LFTs after 2 weeks, and then return to monthly.

*For patients with Crohn’s disease and Ulcerative Colitis, responsibility for monitoring, once stable, rests with the GP.*
**Action to be taken if abnormal results/adverse effects:**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Action</th>
</tr>
</thead>
<tbody>
<tr>
<td>WBC&lt; 3.5 x 10^9/l</td>
<td>Check neutrophil count</td>
</tr>
<tr>
<td>Neutrophils &lt;2.0 x 10^9/l</td>
<td>Monitor weekly, if it falls below 1.5 x 10^9/l STOP DRUG and contact GI consultant.</td>
</tr>
<tr>
<td>Platelets &lt;150 x 10^9/l</td>
<td>Monitor weekly, if it falls below 100 x 10^9/l contact hospital</td>
</tr>
<tr>
<td>3 fold rise in ALT/AST</td>
<td>Monitor weekly, if ALT continues to rise, contact hospital</td>
</tr>
<tr>
<td>Rash</td>
<td>Mild – drug can be continued at reduced dose if necessary</td>
</tr>
<tr>
<td>Oral ulceration</td>
<td>Severe – STOP azathioprine / mercaptopurine and contact the hospital</td>
</tr>
<tr>
<td>MCV&gt; 105fl</td>
<td>Repeat FBC and act on results as above</td>
</tr>
<tr>
<td>Abnormal bruising</td>
<td>Mild – salt water mouth wash.</td>
</tr>
<tr>
<td>Sore throat</td>
<td>Moderate – Hydrocortisone mucoadhesive buccal tablets 2.5 mg (1 applied to affected area qds) and STOP azathioprine / mercaptopurine for at least one week and if resolved, restart but consider reduced dose.</td>
</tr>
<tr>
<td>Drug related acute shortness of breath</td>
<td>Severe – STOP azathioprine / mercaptopurine. Prescribe hydrocortisone mucoadhesive buccal tablets 2.5mg and contact hospital.</td>
</tr>
<tr>
<td>Sudden cough</td>
<td>Check B12 and Folate and, if low, start appropriate supplements</td>
</tr>
<tr>
<td>Drug related acute shortness of breath</td>
<td>Repeat FBC and act on results as above</td>
</tr>
<tr>
<td>Drug related acute shortness of breath</td>
<td>Repeat FBC and act on results as above</td>
</tr>
<tr>
<td>Drug related acute shortness of breath</td>
<td>STOP DRUG, contact hospital and if severe, refer to Medical Assessment Unit, Arrowe Park Hospital.</td>
</tr>
</tbody>
</table>

Please note that in addition to absolute values for haematological indices, a rapid fall or a consistent downward trend in any value should prompt caution and extra vigilance.

**Contraindications:**

- Azathioprine and mercaptopurine should not be given to women who are pregnant, or likely to become pregnant without a careful assessment of risk versus benefit.
- Absent TPMT
- Live vaccines are contra-indicated in patients receiving azathioprine and mercaptopurine on theoretical grounds.
- Hypersensitivity to azathioprine or mercaptopurine

**Drug interactions:**

- Azathioprine and mercaptopurine activity is inhibited by allopurinol - avoid co-prescription where possible. If essential, contact helpline for advice on azathioprine/ mercaptopurine dose reduction
- Azathioprine and mercaptopurine can inhibit the anticoagulant effect of warfarin.
- Avoid co-prescription of drugs that may have a myelosuppressive effect, such as penicillamine, co-trimoxazole, ACE inhibitors, cimetidine or indomethacin as serious haematological abnormalities may result.
- For patients with an inherited deficiency of the TPMT enzyme, lower doses of azathioprine/ mercaptopurine should be used and it should also be administered with caution in patients receiving aminosalicylate derivatives eg olsalazine, mesalazine or sulfasalazine as these drugs inhibit TPMT.
- A diminished response to killed vaccines is likely.

**Cautions:**

- Renal or hepatic insufficiency may enhance the toxicity of azathioprine and mercaptopurine. The haematological response should be carefully monitored and doses at the lower end of the range should be used.
- Increased risk of skin cancers; avoid exposure to sunlight and UV light by using sunscreen and protective clothing.

**Adverse Effects:**

- Depression of bone marrow function, leucopenia, thrombocytopenia, anaemia and other blood disorders.
- Viral, fungal and bacterial infections.
- Neoplasms, including non-Hodgkin’s Lymphomas, skin cancers, sarcomas and uterine cervical cancer.
- Nausea, pancreatitis, altered liver function, alopecia, hypersensitivity reactions, SJS, toxic epidermal necrolysis.

**Specialist responsibilities:**

1. Confirm the diagnosis of Inflammatory Bowel Disease (IBD) and discuss with the patient the benefits and side effects of treatment with azathioprine/ mercaptopurine. If the patient is a woman of child bearing potential ensure that they are aware of the importance of effective contraception and the need to discuss with their consultant if they wish to become pregnant.
2. Ensure baseline monitoring of full blood count, biochemical profile and TPMT, also subsequent monitoring until dose is stabilised.

3. Review the patient after one month (this can be in the gastroenterology specialist nurse clinic) and if the patient is tolerating and benefiting from azathioprine/ mercaptopurine at this first visit, a written request should be made to the GP to continue prescribing the medication and to continue the monitoring.

4. Prescribe the initial 2 months of azathioprine/ mercaptopurine during the trial period and discontinue if no response or significant adverse effect.

5. Provide the patient with a shared care booklet and enter the blood results into the booklet.

6. Regularly review the patient to monitor efficacy of the treatment and the ability to tolerate it, and consider whether continuation of treatment is appropriate.

7. Communicate promptly with the GP when treatment is changed and each time the patient is seen.

8. Undertake any necessary monitoring at review appointments.

9. Ensure clear backup arrangements exist for GPs for advice and support.

10. Report serious adverse events to the Committee on Safety of Medicines (CSM).

**GP responsibilities:**

1. Initial referral to Consultant Gastroenterologist raising the possibility of IBD.

2. Provide the patient with monthly repeat prescriptions of medication once the specialist has recommended continuation therapy.

3. Continue monitoring as outlined on the first page and document the results in the shared care booklet.

4. Ensure patient’s shared care booklet and practice computer system are updated with any dose changes.

5. Report any adverse effects to the consultant.

6. Refer back to the consultant if the patient’s condition deteriorates or if there is a change in the patient’s status.

7. Contact the consultant if they do not agree with the treatment recommendation, or if there is a perceived problem with compliance or concordance, or if they have any questions about the management plan.

8. Administer Pneumovac® II and annual influenza vaccines.

9. Administer Varicella Zoster Immunoglobulin in non-immune patients exposed to chickenpox or shingles.

**Patient responsibilities:**

1. Read the written information provided about the drug and have a clear understanding of the risks / benefits of oral azathioprine/ mercaptopurine treatment.

2. Attend for blood tests.

3. Allow at least 48 hours for the prescription from the GP to be generated once they have agreed to take on prescribing.

4. Report any adverse effects, concerns or lack of understanding of the treatment to the GP or specialist.

5. Limit alcohol to national safe limits.

6. Take monitoring booklet every time the patient sees their GP, has a hospital appointment or visits the pharmacist.

**Secondary care review:** Patients will be reviewed one month after starting azathioprine/ mercaptopurine and thereafter at a frequency determined by the clinical need by the consultant clinic, or if requested to review by the GP.

**Availability:**

- Azathioprine 25mg tablet: 28 = £3.91
- 50mg tablet: 56 = £3.54
- Mercaptopurine 50mg tablet: 25 = £50.47

*Prices from Drug Tariff November 2014*

**Back up advice and support:** IBD Specialist Nurse  
**Telephone:** 0151 604 7459  
**Email:** wih-tr.IBDnurses1@nhs.net

**Written By:** Helen Dingle, Prescribing Adviser, Medicines Management Team, Wirral (amended by Aine McManus (Pharmacist APH))  
Dr G Pritchard, Consultant Gastroenterologist and IBD Lead, Wirral University Teaching Hospital NHS Trust